m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03438
 [1], [2]
Histone modification H3K27ac HDAC1 FTO Direct Inhibition m6A modification MTOR MTOR FTO Demethylation : m6A sites
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
m6A Target Serine/threonine-protein kinase mTOR (MTOR)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone deacetylase 1 (HDAC1) ERASER View Details
Regulated Target Histone H3 lysine 27 acetylation (H3K27ac) View Details
Downstream Gene FTO View Details
Crosstalk Relationship Histone modification  →  m6A Inhibition
Crosstalk Mechanism histone modification directly impacts m6A modification through modulating the level of m6A regulator
Crosstalk Summary HDACi reduces ferroptosis suppressor protein (FSP1) by promoting its mRNA degradation. Specifically, it is confirmed that HDACi specifically targets HDAC1 and promotes the Histone H3 lysine 27 acetylation (H3K27ac) modification of fat mass- and obesity-associated gene (FTO) and AlkB Homolog 5, RNA Demethylase (ALKBH5), which results in significant activation of FTO and ALKBH5. The activation of FTO and ALKBH5 reduces N6-methyladenosine (m6A) modification on FSP1 mRNA, leading to its degradation. Crucially, lactylation of HDAC1K412is essential for ferroptosis regulation. Both Vorinostat (SAHA) and Trichostatin A (TSA) notably diminish HDAC1K412lactylation in comparison to other HDAC1 inhibitors, exhibiting a consistent trend of increasing susceptibility to ferroptosis. In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Serine/threonine-protein kinase mTOR (MTOR) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition.
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Responsed Drug Rapamycin
 Drug Info 
Pathway Response mTOR signaling pathway hsa04150
Cell Process RNA decay
Cell growth and death
Cell autophagy
In-vitro Model
 SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone deacetylase 1 (HDAC1) 250 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Panobinostat Approved [3]
Synonyms
Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.54 nM
External Link
CID: 6918837
TTD: D0E3SH
DrugBank: DB06603
 Compound Name Vorinostat Approved [3]
Synonyms
NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1.3 nM
External Link
CID: 5311
TTD: D0E7PQ
DrugBank: DB02546
 Compound Name Romidepsin Approved [4]
Synonyms
Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.0015 nM
External Link
CID: 5352062
TTD: D0L7LC
DrugBank: DB06176
 Compound Name HBI-8000 Phase 1/2 [5]
Synonyms
CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
    Click to Show/Hide
MOA Modulator
Activity IC50 = 167 nM
External Link
CID: 12136798
TTD: D00SQN
DrugBank: DB06334
 Compound Name NVP-LAQ824 Phase 3 [6]
Synonyms
Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.55 nM
External Link
CID: 6445533
TTD: D0B3FV
 Compound Name SNDX-275 Phase 3 [7]
Synonyms
Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 22 nM
External Link
CID: 4261
TTD: D0M8FD
DrugBank: DB11841
 Compound Name ITF2357 Phase 3 [8]
Synonyms
Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 2 nM
External Link
CID: 9804992
TTD: D0GH3Q
DrugBank: DB12645
 Compound Name Resminostat Phase 2 [9]
Synonyms
864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11609955
TTD: D01UXJ
DrugBank: DB12392
 Compound Name Sodium butyrate Phase 2 [10]
Synonyms
Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5222465
TTD: D0I7IB
 Compound Name SB-623 Phase 2 [11]
Synonyms
(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 52 nM
External Link
CID: 6918876
TTD: D0VE1W
 Compound Name MGCD-0103 Phase 2 [3]
Synonyms
Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 9 nM
External Link
CID: 9865515
TTD: D00FHR
DrugBank: DB11830
 Compound Name Phenylbutyrate Phase 2 [12]
Synonyms
Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 64000 nM
External Link
CID: 4775
TTD: D0B7CH
DrugBank: DB06819
 Compound Name CHR-3996 Phase 1/2 [13]
Synonyms
CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 49857317
TTD: D06TKI
DrugBank: DB15419
 Compound Name SB-639 Phase 1 [11]
Synonyms
CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 11 nM
External Link
CID: 6918877
TTD: D07FPY
 Compound Name RG-2833 Phase 1 [5]
Synonyms
RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen
    Click to Show/Hide
MOA Modulator
Activity Ki = 32 nM
External Link
CID: 56654642
TTD: D0GE5B
 Compound Name OBP-801 Phase 1 [14]
MOA Inhibitor
Activity IC50 = 3.3 nM
External Link
CID: 11178958
TTD: D00SSZ
DrugBank: DB12279
 Compound Name PMID29671355-Compound-42 Patented [15]
MOA Inhibitor
Activity IC50 = 10 to 100 nM
External Link
CID: 118366974
TTD: D0YT8O
 Compound Name PMID28092474-Compound-33d Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
CID: 117703486
TTD: D00ACL
 Compound Name PMID28092474-Compound-32u Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D00GLJ
 Compound Name PMID28092474-Compound-33a Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D00LLN
 Compound Name PMID28092474-Compound-32a Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D00XWZ
 Compound Name PMID28092474-Compound-32j Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D01LCZ
 Compound Name PMID28092474-Compound-32z Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D02YDG
 Compound Name PMID28092474-Compound-32g Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D03EUD
 Compound Name PMID28092474-Compound-34c Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D04AMI
 Compound Name PMID28092474-Compound-32x Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 117703583
TTD: D04KQU
 Compound Name PMID28092474-Compound-33b Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D04MVN
 Compound Name PMID28092474-Compound-32b Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
CID: 86282589
TTD: D04VQE
 Compound Name PMID28092474-Compound-32o Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 86282321
TTD: D06IIL
 Compound Name PMID28092474-Compound-33g Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
CID: 117703541
TTD: D08GBR
 Compound Name PMID28092474-Compound-33j Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 117703439
TTD: D08GQL
 Compound Name PMID28092474-Compound-33p Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D08SNJ
 Compound Name PMID28092474-Compound-33m Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D08XLK
 Compound Name PMID28092474-Compound-32v Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D08ZJZ
 Compound Name PMID29671355-Compound-24 Patented [15]
MOA Inhibitor
Activity IC50 = 382 nM
External Link
TTD: D09PVH
 Compound Name PMID28092474-Compound-34b Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0BY1R
 Compound Name PMID28092474-Compound-33e Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0CH4M
 Compound Name PMID28092474-Compound-32t Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 86282179
TTD: D0CX1Y
 Compound Name PMID28092474-Compound-32c Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0DH7R
 Compound Name PMID28092474-Compound-33i Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0E5CO
 Compound Name PMID28092474-Compound-32r Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 86282178
TTD: D0ET4U
 Compound Name PMID28092474-Compound-32h Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0EU5A
 Compound Name PMID29671355-Compound-65a Patented [15]
MOA Inhibitor
Activity IC50 = 13800 nM
External Link
CID: 126720707
TTD: D0F3TB
 Compound Name PMID28092474-Compound-32y Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0HM6Y
 Compound Name PMID28092474-Compound-33h Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0JN0A
 Compound Name PMID29671355-Compound-38a Patented [15]
MOA Inhibitor
Activity IC50 > 1000 nM
External Link
CID: 121304883
TTD: D0JR9L
 Compound Name PMID28092474-Compound-33f Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0K2UF
 Compound Name Diaryl amine derivative 3 Patented [16]
Synonyms
PMID28092474-Compound-11
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 460 nM
External Link
TTD: D0KA3X
 Compound Name PMID28092474-Compound-33c Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0L3CU
 Compound Name PMID29671355-Compound-39 Patented [15]
MOA Inhibitor
Activity IC50 = 3840 nM
External Link
CID: 124093354
TTD: D0L7HG
 Compound Name PMID29671355-Compound-19 Patented [15]
MOA Inhibitor
Activity IC50 = 500 to 1000 nM
External Link
TTD: D0LV6K
 Compound Name PMID28092474-Compound-32e Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0M7XL
 Compound Name PMID28092474-Compound-32m Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 117703481
TTD: D0MQ2D
 Compound Name PMID28092474-Compound-32p Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 86282322
TTD: D0MR7U
 Compound Name PMID28092474-Compound-32d Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 86282452
TTD: D0N1RX
 Compound Name PMID28092474-Compound-32n Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 86282455
TTD: D0O6SJ
 Compound Name PMID28092474-Compound-33k Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0Q9XK
 Compound Name PMID28092474-Compound-32k Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0QF0Y
 Compound Name PMID28092474-Compound-34a Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0QN8W
 Compound Name Isosteric imidazolyl pyrimidine derivative 1 Patented [17]
Synonyms
PMID26161698-Compound-37
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 656 nM
External Link
CID: 44555024
TTD: D0QR1Z
 Compound Name PMID29671355-Compound-22 Patented [15]
MOA Inhibitor
Activity IC50 = 2100 nM
External Link
CID: 71532921
TTD: D0QX3G
 Compound Name PMID29671355-Compound-26 Patented [15]
MOA Inhibitor
Activity IC50 = 8750 nM
External Link
CID: 130361892
TTD: D0R3RJ
 Compound Name PMID28092474-Compound-33o Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0RD7T
 Compound Name PMID28092474-Compound-32f Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0S3ZB
 Compound Name Diaryl amine derivative 2 Patented [16]
Synonyms
PMID28092474-Compound-10
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 240 nM
External Link
TTD: D0S7NE
 Compound Name PMID28092474-Compound-33l Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0SF8N
 Compound Name PMID28092474-Compound-32i Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
TTD: D0SK9K
 Compound Name PMID28092474-Compound-32q Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 86282451
TTD: D0TH3L
 Compound Name PMID29671355-Compound-18 Patented [15]
MOA Inhibitor
Activity IC50 > 10000 nM
External Link
CID: 86302675
TTD: D0TN6E
 Compound Name PMID29671355-Compound-57 Patented [15]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
TTD: D0UD9R
 Compound Name PMID29671355-Compound-27 Patented [15]
MOA Inhibitor
Activity IC50 = 187 nM
External Link
CID: 130227480
TTD: D0V5IQ
 Compound Name PMID28092474-Compound-32l Patented [16]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
TTD: D0W1AX
 Compound Name PMID28092474-Compound-32s Patented [16]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 117703493
TTD: D0YC2M
 Compound Name PMID29671355-Compound-38b Patented [15]
MOA Inhibitor
Activity IC50 = 226 nM
External Link
CID: 73774655
TTD: D0YD7B
 Compound Name PMID29671355-Compound-28 Patented [15]
MOA Inhibitor
Activity IC50 = 28 nM
External Link
TTD: D0Z7QI
 Compound Name PMID29671355-Compound-59 Patented [15]
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 130319551
TTD: D0C9NX
 Compound Name PMID29671355-Compound-55 Patented [15]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 60198673
TTD: D0OU0J
 Compound Name PMID29671355-Compound-73 Patented [15]
MOA Inhibitor
Activity IC50 = 1000 nM
External Link
CID: 124194015
TTD: D0T7OQ
 Compound Name PMID29671355-Compound-13 Patented [15]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
CID: 71811260
TTD: D0ZG5X
 Compound Name PMID29671355-Compound-11 Patented [15]
MOA Inhibitor
Activity IC50 = 21 nM
External Link
CID: 118005782
TTD: D0EH2K
 Compound Name PMID29671355-Compound-9 Patented [15]
MOA Inhibitor
Activity IC50 = 94 nM
External Link
CID: 57381425
TTD: D0Q1QY
 Compound Name PMID29671355-Compound-8 Patented [15]
MOA Inhibitor
Activity IC50 = 16900 nM
External Link
TTD: D0LN1T
 Compound Name PMID29671355-Compound-61 Patented [15]
MOA Inhibitor
Activity IC50 = 2.6 nM
External Link
TTD: D0JB4S
 Compound Name PMID29671355-Compound-23 Patented [15]
MOA Inhibitor
Activity IC50 = 3620 nM
External Link
CID: 118884610
TTD: D00HXJ
 Compound Name PMID29671355-Compound-44 Patented [15]
MOA Inhibitor
Activity IC50 < 150 nM
External Link
CID: 72710871
TTD: D0N2DK
 Compound Name PMID29671355-Compound-56 Patented [15]
MOA Inhibitor
Activity IC50 = 8700 nM
External Link
CID: 56965342
TTD: D0CH8Q
 Compound Name PMID29671355-Compound-67 Patented [15]
MOA Inhibitor
Activity IC50 = 2900 nM
External Link
CID: 60201048
TTD: D0M0RE
 Compound Name PMID29671355-Compound-31 Patented [15]
MOA Inhibitor
Activity IC50 = 0.3 nM
External Link
CID: 90479372
TTD: D0DI9S
DrugBank: DB14979
 Compound Name PMID29671355-Compound-21 Patented [15]
MOA Inhibitor
Activity IC50 = 2120 nM
External Link
CID: 86295624
TTD: D0LP1K
 Compound Name PMID29671355-Compound-62 Patented [15]
MOA Inhibitor
Activity IC50 = 100 to 500 nM
External Link
TTD: D07WAT
 Compound Name PMID29671355-Compound-43 Patented [15]
MOA Inhibitor
Activity IC50 = 23 nM
External Link
CID: 118515590
TTD: D0BP8I
 Compound Name PMID29671355-Compound-25 Patented [15]
MOA Inhibitor
Activity IC50 = 175 nM
External Link
CID: 126569528
TTD: D0RA0D
 Compound Name AN-9 Discontinued in Phase 2 [10]
Synonyms
Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 60748
TTD: D0MP2U
DrugBank: DB05103
 Compound Name Tacedinaline Discontinued in Phase 2 [11]
Synonyms
Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 50 nM
External Link
CID: 2746
TTD: D0W9NH
DrugBank: DB12291
 Compound Name Pyroxamide Discontinued in Phase 1 [11]
Synonyms
POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 2.7 nM
External Link
CID: 4996
TTD: D0N3SH
DrugBank: DB12847
 Compound Name M-carboxycinnamic acid bishydroxamide Preclinical [11]
Synonyms
Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 5353484
TTD: D03SZR
 Compound Name HC-Toxin Preclinical [11]
Synonyms
HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 107864
TTD: D06RQU
 Compound Name SK-7068 Preclinical [11]
Synonyms
N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9799221
TTD: D0DO5U
 Compound Name Scriptaid Preclinical [11]
Synonyms
CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1.5 nM
External Link
CID: 5186
TTD: D0J8OC
 Compound Name 4SC-202 Preclinical [9]
MOA Inhibitor
External Link
CID: 44217246
TTD: D0L5DZ
 Compound Name Chlamydocin Preclinical [11]
Synonyms
HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 124134
TTD: D0UC6H
 Compound Name SK-7041 Preclinical [11]
Synonyms
IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 6918714
TTD: D0UL5X
 Compound Name Depudecin Preclinical [11]
Synonyms
(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16219259
TTD: D0W8JE
 Compound Name Oxamflatin Terminated [11]
Synonyms
NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5353852
TTD: D03YVR
 Compound Name 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide Investigative [18]
Synonyms
UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 16 nM
External Link
CID: 11449246
TTD: D00GBB
 Compound Name N,8-dihydroxy-8-(naphthalen-2-yl)octanamide Investigative [19]
Synonyms
CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 35 nM
External Link
CID: 11044829
TTD: D00LSZ
 Compound Name N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide Investigative [20]
Synonyms
CHEMBL216292; SCHEMBL5903988
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1130 nM
External Link
CID: 44418106
TTD: D00PLM
 Compound Name N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide Investigative [19]
Synonyms
CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 153 nM
External Link
CID: 11128726
TTD: D00RGD
 Compound Name NSC-746457 Investigative [21]
MOA Inhibitor
Activity IC50 = 104 nM
External Link
CID: 135903324
TTD: D01EDB
 Compound Name 4-Benzenesulfonylamino-N-hydroxy-benzamide Investigative [22]
Synonyms
CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 5000 nM
External Link
CID: 44328873
TTD: D02VVU
 Compound Name N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide Investigative [19]
Synonyms
CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 35 nM
External Link
CID: 11129854
TTD: D03FFI
 Compound Name 4-tert-butyl-N-hydroxybenzamide Investigative [23]
Synonyms
62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 715 nM
External Link
CID: 21397854
TTD: D03FOD
 Compound Name N-hydroxy-7-(naphthalen-2-yloxy)heptanamide Investigative [24]
Synonyms
CHEMBL217083
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.9 nM
External Link
CID: 16655084
TTD: D03OYL
 Compound Name 8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide Investigative [18]
Synonyms
CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8280 nM
External Link
CID: 11381650
TTD: D03ZUZ
 Compound Name N-hydroxy-8-(naphthalen-2-yl)non-8-enamide Investigative [19]
Synonyms
CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8 nM
External Link
CID: 11822609
TTD: D04XPZ
 Compound Name N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide Investigative [20]
Synonyms
CHEMBL216509; SCHEMBL5903774; BDBM50198477
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 243 nM
External Link
CID: 10242569
TTD: D05PYF
 Compound Name N-hydroxy-5-phenylthiophene-2-carboxamide Investigative [20]
Synonyms
CHEMBL217573; SCHEMBL5903684
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 900 nM
External Link
CID: 25002768
TTD: D06NVX
 Compound Name Azithromycin-N-benzyltriazolyldecahydroxamic Acid Investigative [25]
Synonyms
CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25190759
TTD: D06ONC
 Compound Name 7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide Investigative [24]
Synonyms
CHEMBL265479
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 18.8 nM
External Link
CID: 44418155
TTD: D07HUH
 Compound Name 8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide Investigative [19]
Synonyms
CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5 nM
External Link
CID: 10314237
TTD: D0A6CB
 Compound Name N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide Investigative [20]
Synonyms
CHEMBL217816; SCHEMBL5903934
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1260 nM
External Link
CID: 44418125
TTD: D0A7IF
 Compound Name Gymnochrome E Investigative [26]
MOA Inhibitor
Activity IC50 = 10900 nM
External Link
CID: 135894458
TTD: D0B1YM
 Compound Name N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide Investigative [19]
Synonyms
CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6 nM
External Link
CID: 10891349
TTD: D0CJ7L
 Compound Name N-hydroxybenzo[b]thiophene-2-carboxamide Investigative [27]
Synonyms
CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 670 nM
External Link
CID: 11708207
TTD: D0D3XC
 Compound Name 7-(1H-indol-5-yloxy)-N-hydroxyheptanamide Investigative [24]
Synonyms
CHEMBL426516
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.6 nM
External Link
CID: 44418145
TTD: D0G0OF
 Compound Name 8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide Investigative [19]
Synonyms
CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 45 nM
External Link
CID: 11120992
TTD: D0GJ1E
 Compound Name N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide Investigative [19]
Synonyms
CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 450 nM
External Link
CID: 10858374
TTD: D0K8MF
 Compound Name N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide Investigative [19]
Synonyms
CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 95 nM
External Link
CID: 11821974
TTD: D0KM7H
 Compound Name N-hydroxy-6-oxo-6-phenylhexanamide Investigative [19]
Synonyms
CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1500 nM
External Link
CID: 11031415
TTD: D0L4ML
 Compound Name N-hydroxy-8-(naphthalen-2-yl)octanamide Investigative [19]
Synonyms
CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 25 nM
External Link
CID: 11833001
TTD: D0L5WI
 Compound Name ADS-102550 Investigative [20]
Synonyms
CHEMBL217716; SCHEMBL5903759; BDBM50198218
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 29 nM
External Link
CID: 10452725
TTD: D0M0QJ
 Compound Name N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide Investigative [19]
Synonyms
CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 15 nM
External Link
CID: 10923922
TTD: D0O7UF
 Compound Name N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide Investigative [28]
Synonyms
CHEMBL238569; SCHEMBL1064835
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1000 nM
External Link
CID: 9924962
TTD: D0P1RQ
 Compound Name N-hydroxy-2,2'-bithiophene-5-carboxamide Investigative [20]
Synonyms
CHEMBL217750; SCHEMBL5903723; BDBM50198479
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2500 nM
External Link
CID: 44418185
TTD: D0PP3Q
 Compound Name ADS-100380 Investigative [20]
Synonyms
CHEMBL216885; SCHEMBL5904027; BDBM50198221
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 750 nM
External Link
CID: 44418141
TTD: D0Q8QA
 Compound Name N-hydroxy-7-oxo-7-phenylheptanamide Investigative [19]
Synonyms
CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
CID: 10998964
TTD: D0QX6R
 Compound Name 7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide Investigative [18]
Synonyms
CHEMBL1083440; SCHEMBL4922807
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 145 nM
External Link
CID: 11426781
TTD: D0T0BE
 Compound Name SK-683 Investigative [29]
Synonyms
CHEMBL116620; SCHEMBL8089576; BDBM50148757
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1 nM
External Link
CID: 9888071
TTD: D0U3MB
 Compound Name N-hydroxy-9-oxo-9-phenylnonanamide Investigative [19]
Synonyms
CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 135 nM
External Link
CID: 11139963
TTD: D0Z2VP
 Compound Name N-Hydroxy-N'-(4-methylphenyl)octanediamide Investigative [30]
Synonyms
CHEMBL1092762; BDBM50314138
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 76 nM
External Link
CID: 46884057
TTD: D00HFS
 Compound Name N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1093043; BDBM50314143
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141955
TTD: D01AMS
 Compound Name N-(2-aminophenyl)quinoxaline-6-carboxamide Investigative [31]
Synonyms
benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2000 nM
External Link
CID: 23648267
TTD: D01FYB
 Compound Name 7-Biphenyl-4-yl-heptanoic acid hydroxyamide Investigative [32]
Synonyms
CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44349481
TTD: D01RJY
 Compound Name N-(2-Ethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1093040; BDBM50314142
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141752
TTD: D01ZMJ
 Compound Name 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid Investigative [33]
Synonyms
CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44341224
TTD: D03XXI
 Compound Name 1,1,1-Trifluoro-8-phenoxy-octan-2-one Investigative [34]
Synonyms
CHEMBL114796; BDBM50217940
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342886
TTD: D04ETX
 Compound Name 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide Investigative [33]
Synonyms
CHEMBL114184; SCHEMBL3383144
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 22915465
TTD: D04LLD
 Compound Name N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1092032; BDBM50314141
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141956
TTD: D05GRZ
 Compound Name 7-Phenoxy-heptanoic acid hydroxyamide Investigative [32]
Synonyms
CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25798548
TTD: D05ZGM
 Compound Name 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one Investigative [34]
Synonyms
CHEMBL117916; SCHEMBL7366611; BDBM50217945
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342905
TTD: D06BKA
 Compound Name 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide Investigative [35]
Synonyms
CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3074 nM
External Link
CID: 46918725
TTD: D06FAK
 Compound Name Desclasinose Azithromycinarylalkyl Hydroxamate Investigative [25]
Synonyms
CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25151110
TTD: D06THS
 Compound Name N-(4-Ethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1093042; BDBM50314139
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141954
TTD: D08ICY
 Compound Name N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1093713; BDBM50314133
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141960
TTD: D08TIJ
 Compound Name N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide Investigative [36]
Synonyms
CHEMBL473270
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 9 nM
External Link
CID: 44591267
TTD: D08XMS
 Compound Name N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1093357; BDBM50314144
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141957
TTD: D0B8RC
 Compound Name Azithromycin-N-benzyltriazolyloctahydroxamic Acid Investigative [25]
Synonyms
SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25151675
TTD: D0D7KH
 Compound Name N-(4-hydroxybiphenyl-3-yl)benzamide Investigative [37]
Synonyms
CHEMBL269935; SCHEMBL5724398; BDBM50232005
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 58 nM
External Link
CID: 44454650
TTD: D0E0TA
 Compound Name AZUMAMIDE E Investigative [38]
Synonyms
CHEMBL402363
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 50 nM
External Link
CID: 16095101
TTD: D0E9DD
 Compound Name Azithromycin-N-benzyltriazolylnonahydroxamic Acid Investigative [25]
Synonyms
CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25190758
TTD: D0H3RO
 Compound Name N-Hydroxy-N'-(3-methylphenyl)octanediamide Investigative [30]
Synonyms
CHEMBL1089339; BDBM50314136
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 57 nM
External Link
CID: 46884056
TTD: D0H7QA
 Compound Name 8-Phenyl-octanoic acid hydroxyamide Investigative [32]
Synonyms
CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 14098189
TTD: D0H9DS
 Compound Name Azithromycin-N-benzyltriazolylhexahydroxamic Acid Investigative [25]
Synonyms
CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25152062
TTD: D0I5XM
 Compound Name N-(3-Ethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1093041; BDBM50314134
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141753
TTD: D0J3CY
 Compound Name N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1093359; BDBM50314135
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141959
TTD: D0L5KP
 Compound Name N-Hydroxy-N'-(4-methoxyphenyl)octanediamide Investigative [30]
Synonyms
CHEMBL1091487; BDBM50314137
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 71 nM
External Link
CID: 46884016
TTD: D0L6YF
 Compound Name AZUMAMIDE B Investigative [38]
Synonyms
CHEMBL402727
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1830 nM
External Link
CID: 16095112
TTD: D0M1ZI
 Compound Name 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one Investigative [34]
Synonyms
CHEMBL116023; SCHEMBL7368359; BDBM50218558
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44343094
TTD: D0NL6C
 Compound Name Azithromycinarylalkylhydroxamic Acid Investigative [25]
Synonyms
CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25151109
TTD: D0P9CQ
 Compound Name N-Hydroxy-N'-(2-methylphenyl)octanediamide Investigative [30]
Synonyms
CHEMBL1076794; BDBM50314140
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 576 nM
External Link
CID: 46884055
TTD: D0Q2CC
 Compound Name nexturastat A Investigative [39]
Synonyms
S7473
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 360 nM
External Link
CID: 71462653
TTD: D0Q5DI
 Compound Name AZUMAMIDE C Investigative [38]
Synonyms
CHEMBL257972
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 20 nM
External Link
CID: 16095114
TTD: D0Q9PO
 Compound Name N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [30]
Synonyms
CHEMBL1093358; BDBM50314145
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45141958
TTD: D0SQ1F
 Compound Name N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide Investigative [40]
Synonyms
CHEMBL511212; BDBM50258645
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 10383069
TTD: D0YP4F
 Compound Name LARGAZOLE Investigative [41]
Synonyms
CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10.09 nM
External Link
CID: 24757913
TTD: D0Z8PX
 Compound Name Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) Investigative [42]
Synonyms
CHEMBL393260
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 36 nM
External Link
CID: 44437872
TTD: D00XTC
 Compound Name 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide Investigative [43]
Synonyms
CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 48 nM
External Link
CID: 11427204
TTD: D02HVH
 Compound Name Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) Investigative [42]
Synonyms
CHEMBL390991
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.7 nM
External Link
CID: 44437870
TTD: D02NAF
 Compound Name Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) Investigative [42]
Synonyms
CHEMBL394261
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2 nM
External Link
CID: 44437869
TTD: D02NVY
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) Investigative [42]
Synonyms
CHEMBL391384
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5.3 nM
External Link
CID: 44437878
TTD: D03PRG
 Compound Name Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) Investigative [42]
Synonyms
CHEMBL393261
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 170 nM
External Link
CID: 44437873
TTD: D04CDZ
 Compound Name N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide Investigative [40]
Synonyms
CHEMBL512644; SCHEMBL8226957
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 33 nM
External Link
CID: 25032059
TTD: D04DOL
 Compound Name N-(2-aminophenyl)nicotinamide Investigative [37]
Synonyms
N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2600 nM
External Link
CID: 1133083
TTD: D04UVL
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) Investigative [42]
Synonyms
CHEMBL241555
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.2 nM
External Link
CID: 44437879
TTD: D0E8UH
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) Investigative [42]
Synonyms
CHEMBL428737
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 88 nM
External Link
CID: 44437876
TTD: D0G1EX
 Compound Name N-(4-aminobiphenyl-3-yl)nicotinamide Investigative [37]
Synonyms
CHEMBL255805; BDBM50232035
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 48 nM
External Link
CID: 44454415
TTD: D0M9LJ
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) Investigative [42]
Synonyms
CHEMBL238587
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4.7 nM
External Link
CID: 44437875
TTD: D0N5RV
 Compound Name N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide Investigative [37]
Synonyms
CHEMBL256440; SCHEMBL1066609
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 65 nM
External Link
CID: 44454416
TTD: D0Q2GM
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) Investigative [42]
Synonyms
CHEMBL238596; BDBM50222727
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 94 nM
External Link
CID: 44437883
TTD: D0R3XO
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) Investigative [42]
Synonyms
CHEMBL393961
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6.4 nM
External Link
CID: 44437880
TTD: D0U0EZ
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) Investigative [42]
Synonyms
CHEMBL391383
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6.2 nM
External Link
CID: 44437877
TTD: D0X4QC
 Compound Name N-(2-aminophenyl)-4-methoxybenzamide Investigative [31]
Synonyms
AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2000 nM
External Link
CID: 785232
TTD: D0YO6M
 Compound Name Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) Investigative [42]
Synonyms
CHEMBL393464
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.7 nM
External Link
CID: 44437874
TTD: D0Z6HR
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) Investigative [42]
Synonyms
CHEMBL238829; BDBM50222732
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.9 nM
External Link
CID: 44437868
TTD: D0Z6MI
 Compound Name 4-Phenylbutyrohydroxamic acid Investigative [44]
Synonyms
N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 295 nM
External Link
CID: 279980
TTD: D02NWS
 Compound Name 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative [45]
Synonyms
CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 65 nM
External Link
CID: 11075845
TTD: D0S0WK
 Compound Name ST-3050 Investigative [46]
Synonyms
CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3060 nM
External Link
CID: 44591988
TTD: D01YBR
 Compound Name Octanedioic acid bis-hydroxyamide Investigative [47]
Synonyms
Suberohydroxamic acid
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 19 nM
External Link
CID: 5173
TTD: D07YZZ
 Compound Name ST-2986 Investigative [46]
Synonyms
CHEMBL471041; SCHEMBL3444455; BDBM50278219
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5480 nM
External Link
CID: 44138031
TTD: D0N9AK
 Compound Name 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative [34]
Synonyms
9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7800 nM
External Link
CID: 9882812
TTD: D00KFF
DrugBank: DB07553
 Compound Name 7-Mercapto-heptanoic acid phenylamide Investigative [48]
Synonyms
Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 218 nM
External Link
CID: 11379392
TTD: D00SEE
 Compound Name 6-benzenesulfinylhexanoic acid hydroxamide Investigative [49]
Synonyms
6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11694528
TTD: D00ZSD
 Compound Name N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative [50]
Synonyms
CHEMBL193959
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44401339
TTD: D01MFV
 Compound Name 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative [48]
Synonyms
CHEMBL112311
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11220728
TTD: D01XWZ
 Compound Name N-Hydroxy-4-phenylacetylamino-benzamide Investigative [51]
Synonyms
CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11196500
TTD: D01XXN
 Compound Name 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative [48]
Synonyms
CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9927379
TTD: D02MQM
 Compound Name N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative [52]
Synonyms
CHEMBL143674; SCHEMBL673760
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11323577
TTD: D02UTC
 Compound Name 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [53]
Synonyms
CHEMBL126355; BDBM50222394
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350626
TTD: D02WZK
 Compound Name Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative [54]
Synonyms
SCHEMBL8082656; CHEMBL165162; ZINC13472304
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10967421
TTD: D04GGW
 Compound Name N-(6-Mercapto-hexyl)-benzamide Investigative [48]
Synonyms
CHEMBL112364; BDBM50223650
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11447748
TTD: D04HSS
 Compound Name 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative [54]
Synonyms
CHEMBL167455
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11086699
TTD: D04NSP
 Compound Name N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative [51]
Synonyms
SCHEMBL675474
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11231829
TTD: D04ZDI
 Compound Name 6-benzenesulfonylhexanoic acid hydroxamide Investigative [49]
Synonyms
CHEMBL203207
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11572583
TTD: D05AHZ
 Compound Name 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative [34]
Synonyms
SCHEMBL7373122; CHEMBL116578
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342872
TTD: D05FEJ
 Compound Name Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative [48]
Synonyms
CHEMBL111806; SCHEMBL14812153
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11254470
TTD: D05GVY
 Compound Name 4-Butyrylamino-N-hydroxy-benzamide Investigative [52]
Synonyms
CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11287488
TTD: D05LLX
 Compound Name 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [53]
Synonyms
CHEMBL127328
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350703
TTD: D05VFP
 Compound Name 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative [48]
Synonyms
CHEMBL320323
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11449823
TTD: D05XAN
 Compound Name 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative [55]
MOA Inhibitor
External Link
CID: 3082127
TTD: D06IQB
 Compound Name N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative [51]
Synonyms
SCHEMBL676079
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11347053
TTD: D06VBN
 Compound Name 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative [48]
Synonyms
CHEMBL324126
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11277483
TTD: D06XNP
 Compound Name 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative [48]
Synonyms
CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11345433
TTD: D07FJU
 Compound Name 6-Phenoxy-hexane-1-thiol Investigative [48]
Synonyms
CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11298778
TTD: D09YBN
 Compound Name 4-Benzoylamino-N-hydroxy-benzamide Investigative [51]
Synonyms
SCHEMBL673678; CHEMBL191227
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11817702
TTD: D09ZNU
 Compound Name 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative [45]
Synonyms
CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 403373
TTD: D0A5LS
 Compound Name 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative [34]
Synonyms
CHEMBL112148; SCHEMBL7364383; BDBM50218532
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44341053
TTD: D0AX7B
 Compound Name 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [53]
Synonyms
CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350718
TTD: D0B2ZJ
 Compound Name 6-Mercapto-hexanoic acid phenylamide Investigative [48]
Synonyms
CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 791 nM
External Link
CID: 11436024
TTD: D0B3ZM
 Compound Name Cyclostellettamine derivative Investigative [56]
Synonyms
CHEMBL88332
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 23327627
TTD: D0C0VP
 Compound Name N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative [45]
Synonyms
CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9943996
TTD: D0C2KD
 Compound Name 5-Mercapto-pentanoic acid phenylamide Investigative [48]
Synonyms
N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11608171
TTD: D0D2KE
 Compound Name Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative [54]
Synonyms
SCHEMBL8090513; CHEMBL164872; ZINC13472303
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11747496
TTD: D0E8KR
 Compound Name N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative [50]
Synonyms
CHEMBL193979
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44401305
TTD: D0F0KS
 Compound Name 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative [55]
Synonyms
CHEMBL271677; SCHEMBL4156413
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24759251
TTD: D0H1FZ
 Compound Name (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative [53]
Synonyms
CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350655
TTD: D0KE3I
 Compound Name N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative [51]
Synonyms
SCHEMBL676080
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11312563
TTD: D0QO0L
 Compound Name N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative [57]
Synonyms
N-hydroxy-4-(3-phenylpropanamido)benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0R4BS
 Compound Name N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative [51]
Synonyms
SCHEMBL7311087
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11472431
TTD: D0R5VG
 Compound Name 8-Oxo-8-phenyl-octanoic acid Investigative [54]
Synonyms
8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 298878
TTD: D0RU1X
 Compound Name N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative [51]
Synonyms
CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9994848
TTD: D0S7WQ
 Compound Name 6-phenylsulfanylhexanoic acid hydroxamide Investigative [49]
Synonyms
Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11637291
TTD: D0S9JF
 Compound Name ST-2987 Investigative [46]
Synonyms
CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 790 nM
External Link
CID: 44138032
TTD: D0T0SK
 Compound Name 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative [48]
Synonyms
CHEMBL112234
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10379373
TTD: D0T4IY
 Compound Name 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative [58]
Synonyms
CHEMBL84288
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11528707
TTD: D0V2ZO
 Compound Name 8-Mercapto-octanoic acid phenylamide Investigative [48]
Synonyms
8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 294 nM
External Link
CID: 11149404
TTD: D0XZ9Q
 Compound Name N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative [54]
Synonyms
CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9965141
TTD: D0YY9M
 Compound Name 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative [34]
Synonyms
CHEMBL326529; SCHEMBL7365237; BDBM50217957
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342825
TTD: D0Z3BM
 Compound Name 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative [48]
Synonyms
CHEMBL178779
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11346934
TTD: D0Z5KX
 Compound Name N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative [52]
Synonyms
CHEMBL143102
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44361923
TTD: D0Z7YS
 Compound Name PSAMMAPLIN A Investigative [45]
Synonyms
110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 6400741
TTD: D0N0TS
Serine/threonine-protein kinase mTOR (MTOR) 72 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Novolimus Approved [59]
MOA Inhibitor
External Link
CID: 9854320
TTD: D03FCF
 Compound Name Temsirolimus Approved [60]
Synonyms
Torisel
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1760 nM
External Link
CID: 6918289
TTD: D0ES1Q
 Compound Name Everolimus Approved [61]
Synonyms
Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 6442177
TTD: D0K3QS
DrugBank: DB01590
 Compound Name Zotarolimus Approved [62]
Synonyms
Abt-578; Zotarolimus (TN)
    Click to Show/Hide
MOA Modulator
Activity IC50 = 3.3 nM
External Link
CID: 9876378
TTD: D0V7WS
 Compound Name Sirolimus Approved [63]
Synonyms
53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5284616
TTD: D03LJR
DrugBank: DB00877
 Compound Name PF-04449913 Approved [64]
Synonyms
Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25166913
TTD: D0S5LO
DrugBank: DB11978
 Compound Name Ridaforolimus Phase 3 [65]
Synonyms
Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11520894
TTD: D0O3CV
DrugBank: DB06233
 Compound Name INK128 Phase 2 [66]
Synonyms
1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1 nM
External Link
CID: 45375953
TTD: D03DPZ
DrugBank: DB11836
 Compound Name OSI-027 Phase 2 [67]
MOA Inhibitor
External Link
CID: 135398516
TTD: D0H7XL
DrugBank: DB12387
 Compound Name ABI-009 Phase 2 [68]
MOA Inhibitor
External Link
TTD: D0W3UV
 Compound Name Salirasib Discontinued in Phase 1/2 [59]
Synonyms
162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032
    Click to Show/Hide
MOA Modulator
External Link
CID: 5469318
TTD: D00KTV
DrugBank: DB12681
 Compound Name SAR245409 Phase 2 [59]
MOA Inhibitor
Activity IC50 = 157 nM
External Link
CID: 16123056
TTD: D01PGR
DrugBank: DB12400
 Compound Name SF1126 Phase 2 [68]
Synonyms
CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 66577114
TTD: D03NJY
 Compound Name PF-05212384 Phase 2 [69]
Synonyms
PKI-587; 1197160-78-3; Gedatolisib; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-
    Click to Show/Hide
MOA Modulator
Activity IC50 = 0.4 nM
External Link
CID: 44516953
TTD: D0D8JB
DrugBank: DB11896
 Compound Name LY3023414 Phase 2 [70]
MOA Modulator
External Link
CID: 57519748
TTD: D0H1WC
DrugBank: DB12167
 Compound Name PF-04691502 Phase 2 [71]
Synonyms
1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
    Click to Show/Hide
MOA Modulator
Activity IC50 = 7.9 nM
External Link
CID: 25033539
TTD: D0N5JZ
DrugBank: DB11974
 Compound Name GDC-0980/RG7422 Phase 2 [59]
Synonyms
Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S
    Click to Show/Hide
MOA Modulator
Activity Ki = 17 nM
External Link
CID: 25254071
TTD: D0O6VZ
DrugBank: DB12180
 Compound Name BEZ235 Phase 2 [72]
Synonyms
BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
    Click to Show/Hide
MOA Modulator
Activity IC50 = 5 nM
External Link
CID: 11977753
TTD: D0VG0D
DrugBank: DB11651
 Compound Name MM-141 Phase 2 [68]
MOA Inhibitor
External Link
TTD: D00BUO
 Compound Name PQR309 Phase 2 [59]
Synonyms
Bimiralisib; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 62 nM
External Link
CID: 58507717
TTD: D0TU7B
DrugBank: DB14846
 Compound Name AZD2014 Phase 2 [73]
Synonyms
1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.8 nM
External Link
CID: 25262792
TTD: D0Z2UQ
DrugBank: DB11925
 Compound Name CC-223 Phase 1/2 [74]
Synonyms
GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661
    Click to Show/Hide
MOA Modulator
Activity IC50 = 10 nM
External Link
CID: 58298316
TTD: D05EXN
DrugBank: DB12570
 Compound Name BGT226 Phase 1/2 [75]
Synonyms
BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939
    Click to Show/Hide
MOA Modulator
External Link
CID: 11978790
TTD: D0X7IN
 Compound Name ME-344 Phase 1/2 [76]
Synonyms
NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 68026984
TTD: D03IXK
DrugBank: DB13062
 Compound Name BI 860585 Phase 1 [77]
MOA Inhibitor
External Link
TTD: D08PSC
 Compound Name LAM-001 Phase 1 [78]
MOA Inhibitor
External Link
TTD: D0QN5M
 Compound Name DS-3078 Phase 1 [79]
MOA Modulator
External Link
TTD: D0R9VX
 Compound Name GDC-0349 Phase 1 [80]
Synonyms
MTORC1/2 inhibitors
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 3.8 nM
External Link
CID: 59239165
TTD: D0U8QH
DrugBank: DB13072
 Compound Name CERC 006 Phase 1 [81]
Synonyms
(+/-)-Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexane-1-carboxylic acid; (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; (1r,4r)-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo-[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; 1187559-66-5; 25MKH1SZ0M; 4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid; 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid; 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid; 936890-98-1; 936890-98-1 (free acid); A-1065; AC-31517; AEVI-006; AKOS030238938; AKOS037643584; AM81260; AS-17003; ASP 7486; ASP4786; ASP7486; ASP-7486; BCP02613; BCP9001034; BDBM185151; BRD-K94294671-003-01-3; CCG-268721; CERC 006; CERC006; CERC-006; CHEBI:91363; CHEMBL2132692; CHEMBL3120215; CS-0257; Cyclohexanecarboxylic acid, 4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo(5,1-f)(1,2,4)triazin-7-yl)-, trans-; Cyclohexanecarboxylic acid, 4-[4-amino-5-(7-methoxy-1h-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-, trans-; DB12387; DTXSID901025951; EX-A143; F17371; HMS3656H05; HMS3748I11; HY-10423; J-523839; JROFGZPOBKIAEW-HAQNSBGRSA-N; LS-14875; MLS006011006; NCGC00250395-01; NCGC00386179-01; NCGC00386179-04; NCGC00387858-03; NSC800810; NSC-800810; OSI 027; OSI027; OSI-027; Q27163231; Q27253978; s2624; SB19259; SCHEMBL20482333; SCHEMBL22594988; SCHEMBL22787096; SCHEMBL976795; SCHEMBL976796; SMR004702804; SW220246-1; trans-4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid; TRANS-4-[4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL]CYCLOHEXANECARBOXYLIC ACID; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; trans-4-[4-amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-cyclohexanecarboxylic acid; UNII-25MKH1SZ0M
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135398516
TTD: D1RLY2
DrugBank: DB12387
 Compound Name DS-7423 Phase 1 [82]
MOA Modulator
External Link
TTD: D0X4RT
 Compound Name PWT-33597 Phase 1 [83]
Synonyms
PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics
    Click to Show/Hide
MOA Modulator
External Link
CID: 46917355
TTD: D0Y0FE
 Compound Name VS-5584 Phase 1 [59]
Synonyms
5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877
    Click to Show/Hide
MOA Modulator
External Link
CID: 46912230
TTD: D0U3DP
DrugBank: DB12986
 Compound Name PMID25726713-Compound-49 Patented [84]
MOA Inhibitor
Activity IC50 < 1 nM
External Link
TTD: D07TVO
 Compound Name PMID25726713-Compound-51 Patented [84]
MOA Inhibitor
Activity IC50 < 1 nM
External Link
TTD: D0KH7Q
 Compound Name PMID25726713-Compound-48 Patented [84]
MOA Inhibitor
Activity IC50 < 1 nM
External Link
TTD: D0WJ3W
 Compound Name PMID25726713-Compound-47 Patented [84]
MOA Inhibitor
Activity IC50 < 1 nM
External Link
TTD: D0X5VI
 Compound Name PMID25726713-Compound-50 Patented [84]
MOA Inhibitor
Activity IC50 < 1 nM
External Link
TTD: D0Y8JF
 Compound Name AZD8055 Discontinued in Phase 1/2 [85]
Synonyms
1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
CID: 25262965
TTD: D0K1VK
DrugBank: DB12774
 Compound Name TAFA-93 Discontinued in Phase 1 [86]
Synonyms
MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 54601137
TTD: D0H5MX
 Compound Name SCR-44001 Terminated [87]
Synonyms
MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D05SXC
 Compound Name (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol Investigative [88]
Synonyms
CHEMBL594669; SCHEMBL4442909
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4500 nM
External Link
CID: 25069592
TTD: D00GQM
 Compound Name Rapamycin complexed with immunophilin FKBP12 Investigative [89]
MOA Inhibitor
External Link
TTD: D01AQN
 Compound Name C-16-(S)-3-methylindolerapamycin Investigative [90]
Synonyms
CHEMBL503885
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5 nM
External Link
CID: 44576240
TTD: D02TCF
 Compound Name PF-05094037 Investigative [59]
Synonyms
PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D03XRZ
 Compound Name SX-MTR1 Investigative [59]
Synonyms
MTOR modulators (small peptide mimetics, bladder cancer), Serometrix
    Click to Show/Hide
MOA Modulator
External Link
TTD: D05SOW
 Compound Name 2-(6-morpholino-9H-purin-2-yl)phenol Investigative [88]
MOA Inhibitor
Activity IC50 = 2500 nM
External Link
CID: 135955185
TTD: D07JKB
 Compound Name P-2281 Investigative [59]
Synonyms
MTOR inhibitor (ulcerative colitis), Piramal
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07NFT
 Compound Name X-387 Investigative [59]
Synonyms
MTOR inhibitors (cancer), Shanghai Institute of Materia Medica
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D08BTX
 Compound Name 4-(6-morpholino-9H-purin-2-yl)phenol Investigative [88]
MOA Inhibitor
Activity IC50 = 450 nM
External Link
CID: 135955186
TTD: D09FBN
 Compound Name EM-101 Investigative [59]
Synonyms
EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3971
TTD: D09VHS
 Compound Name EC-0845 Investigative [59]
Synonyms
MTOR modulator (inflammatory disease), Endocyte
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0A8ES
 Compound Name 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine Investigative [88]
Synonyms
CHEMBL604876; SCHEMBL4439490
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2800 nM
External Link
CID: 25074311
TTD: D0AH8Q
 Compound Name SB-2280 Investigative [59]
Synonyms
SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0E1YN
 Compound Name 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine Investigative [88]
Synonyms
CHEMBL608095; SCHEMBL4438208
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3900 nM
External Link
CID: 25074312
TTD: D0F1SI
 Compound Name torin 1 Investigative [91]
Synonyms
Torin-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4.32 nM
External Link
CID: 49836027
TTD: D0H0HR
 Compound Name EC-0565 Investigative [59]
Synonyms
Folate-everolimus conjugate (inflammation), Endocyte
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0H4KF
 Compound Name OXA-01 Investigative [59]
Synonyms
MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45276387
TTD: D0J9PK
 Compound Name AR-mTOR-26 Investigative [59]
Synonyms
AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0N9TK
 Compound Name 2-chloro-N-(6-cyanopyridin-3-yl)propanamide Investigative [92]
Synonyms
1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25141337
TTD: D0P0UV
 Compound Name 3-(6-morpholino-9H-purin-2-yl)phenol Investigative [88]
Synonyms
CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1650 nM
External Link
CID: 16049458
TTD: D0TC5H
 Compound Name AP-21967 Investigative [90]
Synonyms
CHEMBL525042; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 44576241
TTD: D0U8GR
 Compound Name 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine Investigative [88]
Synonyms
CHEMBL611630
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 150 nM
External Link
CID: 46225260
TTD: D0Y1DR
 Compound Name Torin2 Investigative [93]
Synonyms
Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 51358113
TTD: D2B7WM
 Compound Name HM-5016699 Investigative [59]
Synonyms
Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D02ELN
 Compound Name PF-03772304 Investigative [94]
Synonyms
MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D05RSS
 Compound Name PP-242 Investigative [95]
Synonyms
PP242; TORKinib
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8 nM
External Link
CID: 135565635
TTD: D0H2CM
 Compound Name CU-906 Investigative [59]
MOA Inhibitor
External Link
TTD: D0JD4S
 Compound Name P-6915 Investigative [59]
Synonyms
PI3K/mTOR inhibitors (cancer), Piramal
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0QE9F
 Compound Name 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one Investigative [96]
Synonyms
Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5300 nM
External Link
CID: 10039361
TTD: D0T0BY
 Compound Name 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one Investigative [96]
Synonyms
CHEMBL435507; SCHEMBL3545107
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4800 nM
External Link
CID: 10017389
TTD: D0X7TB
 Compound Name Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate Investigative [96]
Synonyms
2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6400 nM
External Link
CID: 9860529
TTD: D0W1ST
 Compound Name PP121 Investigative [95]
Synonyms
PP-121; PP 121
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 24905142
TTD: D03EHM
DrugBank: DB08052
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [97]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
TTD: D0PG5O
 Compound Name Aflibercept Approved [98]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
TTD: D0C9ET
 Compound Name Regorafenib Approved [99]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
CID: 11167602
TTD: D09GDD
DrugBank: DB08896
 Compound Name Bevacizumab Approved [68]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name SYM-004 Phase 3 [68]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
TTD: D0CR8H
 Compound Name Bevacizumab + Erlotinib Phase 3 [100]
External Link
TTD: D09BKY
 Compound Name CPI-613 Phase 3 [68]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Bevacizumab Approved [98]
External Link
TTD: D0FX3U
 Compound Name AlloStim Phase 2/3 [101]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
TTD: D0B3CC
 Compound Name Sibrotuzumab Phase 2 [102]
External Link
TTD: DVX3H0
 Compound Name CV301 Phase 2 [103]
External Link
TTD: D9LT5G
 Compound Name Efatutazone Phase 2 [104]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9832447
TTD: D0Y8NZ
DrugBank: DB11894
 Compound Name LOR-2040 Phase 2 [105]
External Link
TTD: D0I7NG
 Compound Name RG7221 Phase 2 [106]
External Link
TTD: D06FTM
 Compound Name PEG-SN38 Phase 2 [107]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
CID: 59443782
TTD: D05UFP
 Compound Name MEGF0444A Phase 2 [108]
External Link
TTD: D01LES
 Compound Name Encapsulated cell therapy Phase 1/2 [109]
External Link
TTD: D0XY8C
 Compound Name AB928 Phase 1/2 [110]
External Link
CID: 135242184
TTD: D04UBI
 Compound Name MGD007 Phase 1 [106]
External Link
TTD: D00PEN
 Compound Name BNC-101 Phase 1 [111]
External Link
TTD: DD6AZ5
 Compound Name Navicixizumab Phase 1 [68]
External Link
TTD: D00IVN
 Compound Name RG7160 Discontinued in Phase 2 [112]
External Link
TTD: D0E2CQ
 Compound Name Nimesulide Terminated [113]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
CID: 4495
TTD: D0C0JT
DrugBank: DB04743
 Compound Name Saracatinib Phase 2 [114]
External Link
CID: 10302451
TTD: D05YTN
DrugBank: DB11805
 Compound Name G3139 + Irinotecan Investigative [115]
External Link
CID: 91865905
TTD: D05IAN
References
Ref 1 Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer. Adv Sci (Weinh). 2025 Mar;12(12):e2408845. doi: 10.1002/advs.202408845. Epub 2025 Jan 31.
Ref 2 Targeting ATF4-dependent pro-survival autophagy to synergize glutaminolysis inhibition. Theranostics. 2021 Jul 25;11(17):8464-8479. doi: 10.7150/thno.60028. eCollection 2021.
Ref 3 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
Ref 4 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. doi: 10.1038/nrd3101.
Ref 5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 6 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
Ref 7 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 8 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. doi: 10.1517/14728210903066809.
Ref 9 2011 Pipeline of 4SC AG.
Ref 10 Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
Ref 11 Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
Ref 12 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 13 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.
Ref 14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2658).
Ref 15 HDAC inhibitors: a 2013-2017 patent survey. Expert Opin Ther Pat. 2018 Apr 19:1-17. doi: 10.1080/13543776.2018.1459568. Online ahead of print.
Ref 16 Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
Ref 17 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014). Expert Opin Ther Pat. 2015;25(9):953-70. doi: 10.1517/13543776.2015.1045414. Epub 2015 Jul 13.
Ref 18 Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3314-21.
Ref 19 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
Ref 20 Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
Ref 21 Histone deacetylase inhibitors through click chemistry. J Med Chem. 2008 Dec 11;51(23):7417-27.
Ref 22 Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett. 2001 Nov 5;11(21):2847-50.
Ref 23 Design of novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4619-24.
Ref 24 Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41.
Ref 25 Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
Ref 26 Gymnochromes E and F, cytotoxic phenanthroperylenequinones from a deep-water crinoid, Holopus rangii. J Nat Prod. 2010 Apr 23;73(4):712-5.
Ref 27 Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29.
Ref 28 N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6729-33.
Ref 29 On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J Med Chem. 2004 Jun 17;47(13):3409-17.
Ref 30 Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
Ref 31 Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. doi: 10.1021/jm701079h. Epub 2007 Oct 17.
Ref 32 A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. doi: 10.1016/j.bmcl.2003.07.012.
Ref 33 Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5. doi: 10.1016/s0960-894x(03)00685-1.
Ref 34 Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. doi: 10.1016/s0960-894x(02)00754-0.
Ref 35 Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70.
Ref 36 Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
Ref 37 SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. doi: 10.1016/j.bmcl.2008.10.052. Epub 2008 Oct 14.
Ref 38 Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
Ref 39 Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9.
Ref 40 Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
Ref 41 Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010 Jun 24;53(12):4654-67.
Ref 42 Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
Ref 43 Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38.
Ref 44 Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. doi: 10.1038/nchembio.313. Epub 2010 Feb 7.
Ref 45 Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. doi: 10.1021/jm0303094.
Ref 46 N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. doi: 10.1016/j.bmcl.2009.02.029. Epub 2009 Feb 12.
Ref 47 Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J Med Chem. 2002 Jul 18;45(15):3296-309. doi: 10.1021/jm0208119.
Ref 48 Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-32. doi: 10.1021/jm049207j.
Ref 49 Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. doi: 10.1021/jm051010j.
Ref 50 Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. doi: 10.1016/j.bmcl.2005.02.075.
Ref 51 Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. doi: 10.1021/jm0503749.
Ref 52 Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. doi: 10.1021/jm0303655.
Ref 53 Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. doi: 10.1016/j.bmcl.2003.09.007.
Ref 54 Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. doi: 10.1021/jm015568c.
Ref 55 New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. doi: 10.1016/j.bmcl.2008.02.007. Epub 2008 Feb 8.
Ref 56 Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. doi: 10.1016/j.bmcl.2004.02.062.
Ref 57 Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. Eur J Med Chem. 2009 Nov;44(11):4470-6. doi: 10.1016/j.ejmech.2009.06.010. Epub 2009 Jun 17.
Ref 58 Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. doi: 10.1016/j.bmcl.2004.03.012.
Ref 59 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
Ref 60 Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20. doi: 10.1016/j.tips.2014.09.007. Epub 2014 Oct 10.
Ref 61 [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma]. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
Ref 62 Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
Ref 63 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
Ref 64 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 65 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.
Ref 66 2011 Pipeline of Intellikine.
Ref 67 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
Ref 68 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 69 First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95. doi: 10.1158/1078-0432.CCR-14-1306. Epub 2015 Feb 4.
Ref 70 Company report (Lilly)
Ref 71 PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011 Nov;10(11):2189-99. doi: 10.1158/1535-7163.MCT-11-0185. Epub 2011 Jul 12.
Ref 72 The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43.
Ref 73 Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12. doi: 10.1016/j.bbrc.2013.11.099. Epub 2013 Dec 2.
Ref 74 CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015 Jun;14(6):1295-305. doi: 10.1158/1535-7163.MCT-14-1052. Epub 2015 Apr 8.
Ref 75 Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8. doi: 10.1097/CAD.0b013e32834c8683.
Ref 76 National Cancer Institute Drug Dictionary (drug id 728650).
Ref 77 Clinical pipeline report, company report or official report of tatcongress.
Ref 78 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 79 A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, Mol Cancer Ther November,2013, 12, C173.
Ref 80 Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. doi: 10.1021/ml3003132. eCollection 2013 Jan 10.
Ref 81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
Ref 82 Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220. doi: 10.1371/journal.pone.0087220. eCollection 2014.
Ref 83 PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials
Ref 84 Hedgehog inhibitors: a patent review (2013 - present). Expert Opin Ther Pat. 2015 May;25(5):549-65. doi: 10.1517/13543776.2015.1019864. Epub 2015 Mar 1.
Ref 85 Clinical pipeline report, company report or official report of AstraZeneca (2009).
Ref 86 EP patent application no. 2275103, Mtor inhibitors in the treatment of endocrine tumors.
Ref 87 Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010 Sep 24;5(9):e12965. doi: 10.1371/journal.pone.0012965.
Ref 88 Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9. doi: 10.1016/j.bmcl.2009.11.051. Epub 2009 Dec 5.
Ref 89 Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37. doi: 10.1634/theoncologist.6-6-517.
Ref 90 The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401. doi: 10.1074/jbc.M700498200. Epub 2007 Mar 9.
Ref 91 Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53(19):7146-55. doi: 10.1021/jm101144f.
Ref 92 Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2949-52. doi: 10.1016/j.bmcl.2009.04.055. Epub 2009 Apr 18.
Ref 93 Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Anticancer Res. 2016 Jan;36(1):95-102.
Ref 94 Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7. doi: 10.1021/ml300309h. eCollection 2013 Jan 10.
Ref 95 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. doi: 10.1038/nchembio.117. Epub 2008 Oct 12.
Ref 96 Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. J Med Chem. 2005 Jan 27;48(2):569-85. doi: 10.1021/jm049526a.
Ref 97 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 98 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 99 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 100 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 101 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 102 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 103 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 104 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 105 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 106 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 107 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 108 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 109 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 110 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 111 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 112 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 113 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 114 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 115 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.